Clinical Trial Update: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) [Phase 3]

View source ↗

Summary

This clinical trial update reports the Phase 3 DESTINY-Gastric04 study of trastuzumab deruxtecan for HER2-positive gastric cancer or gastroesophageal junction a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING